LAUSR

Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder. Daridorexant improves sleep quality without impairing daytime functioning. We assess the safety and efficacy of this novel drug in the treatment of insomnia. We performed a systematic search for electronic databases in SCOPUS, PubMed, Web of Science and the Cochrane library. Seven randomized controlled trials were included in this review, with 2425 participants enrolled. Daridorexant was superior to placebo in reducing wake time after sleep onset (MD = −13.26; 95% CI, −15.48 to −11.03; P < 0.00001), latency to persistent sleep (MD = −7.23; 95% CI, −9.60 to −4.85; P < 0.00001), with increasing the total sleep time (MD = 14.80; 95% CI, 11.18–18.42; P < 0.00001) and subjective total sleep time (MD = 14.80; 95% CI, 11.18–18.42], P < 0.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR) = 1.19; 95% CI, 1.05–1.35;, P = 0.005], specifically somnolence (RR = 1.19; 95% CI, 1.13–3.23; P = 0.005) and fatigue (RR = 2.01; 95% CI, 1.21–3.36; P = 0.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly higher incidence of adverse events, including somnolence and fatigue.